is semaglutide safe to use for weight loss in non-diabetics Semaglutide Associated With Reduced Risk

(II) Suicide risk would be the same or lower after treatment with GLP-1 RAs compared with the period before treatment

Knowing which foods to avoid during GLP-1 protocols helps prevent triggering or worsening nausea

Phase 3 trial results released in December 2025 showed participants lost an average of 28.7% of their body weight (about 71 pounds) over 68 weeks, the highest weight loss reported for any obesity medication to date

Retatrutide takes this foundation and builds upon it with GIP receptor activation (which enhances insulin response and may reduce GLP-1 related nausea) plus glucagon receptor activation (which increases energy expenditure and fat breakdown)

This is where tirzepatides dual profile is especially relevant